Latest Insider Transactions at Clene Inc. (CLNN)
This section provides a real-time view of insider transactions for Clene Inc. (CLNN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Clene Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Clene Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2022
|
General Resonance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
101,352
-0.63%
|
$202,704
$2.96 P/Share
|
|
Feb 01
2022
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
101,352
+5.97%
|
$202,704
$2.96 P/Share
|
|
Jan 20
2022
|
Reed N Wilcox |
BUY
Exercise of conversion of derivative security
|
Direct |
253,000
+45.73%
|
$0
$0.15 P/Share
|
|
Dec 31
2021
|
Chidozie Ugwumba |
BUY
Other acquisition or disposition
|
Indirect |
4,528,809
+50.0%
|
-
|
|
Dec 10
2021
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
15,000
+0.99%
|
$60,000
$4.87 P/Share
|
|
Dec 09
2021
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
40,000
+2.63%
|
$200,000
$5.0 P/Share
|
|
Dec 08
2021
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
5,000
+0.35%
|
$20,000
$4.93 P/Share
|
|
Dec 06
2021
|
David J Matlin |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
50,000
+25.0%
|
$0
$0.01 P/Share
|
|
Dec 06
2021
|
David J Matlin |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
12,500
+0.86%
|
$0
$0.01 P/Share
|
|
Nov 16
2021
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
20,000
+1.39%
|
$100,000
$5.26 P/Share
|
|
Nov 15
2021
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
15,000
+1.06%
|
$75,000
$5.71 P/Share
|
|
Nov 12
2021
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
10,000
+0.71%
|
$50,000
$5.37 P/Share
|
|
Oct 01
2021
|
Alison Mosca |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
25,000
+0.59%
|
$0
$0.01 P/Share
|
|
Jul 14
2021
|
John Henry Stevens |
BUY
Grant, award, or other acquisition
|
Direct |
14,378
+50.0%
|
-
|
|
Jul 14
2021
|
Alison Mosca |
BUY
Grant, award, or other acquisition
|
Direct |
2,083
+50.0%
|
-
|
|
Jul 14
2021
|
Shalom Jacobovitz |
BUY
Grant, award, or other acquisition
|
Direct |
20,838
+50.0%
|
-
|
|
Jul 14
2021
|
Jonathon Gay |
BUY
Grant, award, or other acquisition
|
Direct |
10,783
+50.0%
|
-
|
|
Jul 14
2021
|
Reed N Wilcox |
BUY
Grant, award, or other acquisition
|
Direct |
27,784
+50.0%
|
-
|
|
Jun 30
2021
|
Robert Dee Etherington Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,076
+50.0%
|
-
|
|
Jun 30
2021
|
Mark Mortenson Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,082
+50.0%
|
-
|
|
Jun 30
2021
|
Robert Glanzman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,281
+50.0%
|
-
|
|
May 24
2021
|
David J Matlin |
BUY
Open market or private purchase
|
Direct |
207,684
+13.09%
|
$1,869,156
$9.63 P/Share
|
|
May 24
2021
|
Alison Mosca |
BUY
Open market or private purchase
|
Indirect |
51,921
+50.0%
|
$467,289
$9.63 P/Share
|